Multinational pharmaceutical business Amgen has agreed to purchase Horizon Therapeutics as it strengthens its rare diseases portfolio. The deal is valued at $27.8bn.
Amgen to purchase Horizon Therapeutics
Share
Join our network of executives who receive the MBS News daily, as well as the insights, analysis and our weekly column in The Weekend Edition.
You’ll be able to unsubscribe at any time.